1 Diabetes in its Historical and Social Context
Keypoints

- Polyuric diseases have been described for over 3500 years. The name “diabetes” comes from the Greek word for a syphon; the sweet taste of diabetic urine was recognized at the beginning of the first millennium, but the adjective “mellitus” (honeyed) was only added by Rollo in the late 18th century.
- The sugar in diabetic urine was identified as glucose by Chevreul in 1815. In the 1840s, Bernard showed that glucose was normally present in blood, and showed that it was stored in the liver (as glycogen) for secretion into the bloodstream during fasting.
- In 1889, Minkowski and von Mering reported that pancreatectomy caused severe diabetes in the dog. In 1893, Laguesse suggested that the pancreatic “islets” described by Langerhans in 1869 produced an internal secretion that regulated glucose metabolism.
- Insulin was discovered in 1921 by Banting, Best, Macleod and Collip in acid-ethanol extracts of pancreas. It was first used for treatment in January 1922.
- Diabetes was subdivided on clinical grounds into diabète maigre (lean subjects) and diabète gras (obese) by Lancereaux in 1880, and during the 1930s by Falta and Himsworth into insulin-sensitive and insulin-insensitive types. These classifications were the forerunners of the etiological classification into type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes.
- Insulin resistance and β-cell failure, the fundamental defects of type 2 diabetes, have been investigated by many researchers. The “insulin clamp” method devised by Andres and DeFronzo was the first accurate technique for measuring insulin action. Maturity-onset diabetes of the young was described as a distinct variant of type 2 diabetes by Tattersall in 1974.
- Lymphocytic infiltration of the islets (insulitis) was described as early as 1901 and highlighted in 1965 by Gepts who suggested that it might be a marker of autoimmunity. Islet cell antibodies were discovered by Doniach and Bottazzo in 1979.
- The primary sequence of insulin was reported in 1955 by Sanger and the three-dimensional structure by Hodgkin in 1969. Proinsulin was discovered by Steiner in 1967, and the sequence of the human insulin gene by Bell in 1980. Yalow and Berson invented the radioimmunoassay for insulin in 1956. The presence of insulin receptors was deduced in 1971 by Freychet, and the receptor protein was isolated in 1972 by Cuatrecasas.
- The various types of diabetic retinopathy were described in the second half of the 19th century as were the symptoms of neuropathy. Albuminuria was noted as a common abnormality in patients with diabetes in the 19th century and a unique type of kidney disease was described in 1936 by Kimmelstiel and Wilson. The concept of a specific diabetic angiopathy was developed by Lundbaek in the early 1950s.
- Milestones in insulin pharmacology have included the invention of delayed-action preparations in the 1930s and 1940s; synthetic human insulin in 1979; and in the 1990s novel insulin analogs by recombinant DNA technology.
- The first sulfonylurea carbutamide was introduced in 1955, followed by tolbutamide in 1957 and chlorpropamide in 1960. The biguanide phenformin became available in 1959 and metformin in 1960.
- That improved glucose control in both type 1 and type 2 diabetes was beneficial was proved by the Diabetes Control and Complications Trial (1993) and the UK Prospective Diabetes Study (1998).
- Landmarks in the treatment of complications include photocoagulation for retinopathy first described by Meyer-Schwickerath; the importance of blood pressure to slow the progression of nephropathy (demonstrated by Mogensen and Parving); the introduction of low-dose insulin in the treatment of diabetic ketoacidosis in the 1970s; and improvements in the care of pregnant women with diabetes pioneered by White and Pedersen.

Ancient times

Diseases with the cardinal features of diabetes mellitus were recognized in antiquity (Table 1.1). A polyuric state was described in an Egyptian papyrus dating from c. 1550 BC, discovered by Georg Ebers (Figure 1.1), and a clearly recognizable description of what would now be called type 1 diabetes was given by Aretaeus of Cappadocia in the 2nd century AD (Figure 1.2a). Aretaeus was the first to use the term “diabetes,” from the Greek word for a syphon, “because the fluid does not remain in the body, but uses the man’s body as a channel whereby to leave it.” His graphic account of the disease highlighted the incessant flow of urine,
Diabetes is a dreadful affliction, not very frequent among men, being a melting down of the flesh and limbs into urine. The patients never stop making water and the flow is incessant, like the opening of aqueducts. Life is short, unpleasant and painful, thirst unquenchable, drinking excessive, and disproportionate to the large quantity of urine, for yet more urine is passed. One cannot stop them either from drinking or making water. If for a while they abstain from drinking, their mouths become parched and their bodies dry; the viscera seem scorched up, the patients are affected by nausea, restlessness and a burning thirst, and within a short time, they expire.

Table 1.1 Milestones in the clinical descriptions of diabetes and its complications.

<table>
<thead>
<tr>
<th>Clinical features of diabetes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ebers papyrus (Egypt, 1500 BC)</td>
<td>Polyuric state</td>
</tr>
<tr>
<td>Sushrut and Charak (India, 5th century BC)</td>
<td>Sugary urine; thin and obese patients distinguished</td>
</tr>
<tr>
<td>Aretaeus (Cappadocia, 2nd century AD)</td>
<td>Polyuric state named “diabetes”</td>
</tr>
<tr>
<td>Chen Chuany (China, 7th century)</td>
<td>Sugary urine</td>
</tr>
<tr>
<td>Avicenna (Arabia, 10th century AD)</td>
<td>Sugary urine; gangrene and impotence as complications</td>
</tr>
<tr>
<td>Diabetic ketoacidosis</td>
<td></td>
</tr>
<tr>
<td>William Prout (England, 1810–1820)</td>
<td>Diabetic coma</td>
</tr>
<tr>
<td>Adolf Kussmaul (Germany, 1874)</td>
<td>Acidotic breathing</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td></td>
</tr>
<tr>
<td>Albert Heyl (Philadelphia, 1880)</td>
<td>Lipemia retinalis</td>
</tr>
<tr>
<td>Retinopathy</td>
<td></td>
</tr>
<tr>
<td>Eduard von Jaeger (Germany, 1855)</td>
<td>General features</td>
</tr>
<tr>
<td>Stephen Mackenzie and Edward Nettleship (England, 1879)</td>
<td>Microaneurysms</td>
</tr>
<tr>
<td>Edward Nettleship (England, 1888)</td>
<td>New vessels, beading of retinal veins</td>
</tr>
<tr>
<td>Julius Hirschberg (Germany, 1890)</td>
<td>Classification of lesions; specific to diabetes</td>
</tr>
<tr>
<td>Neuropathy and foot disease</td>
<td></td>
</tr>
<tr>
<td>John Rollo (England, 1797)</td>
<td>Neuropathic symptoms</td>
</tr>
<tr>
<td>Marchal de Calvi (France, 1864)</td>
<td>Neuropathy is a complication of diabetes</td>
</tr>
<tr>
<td>William Ogle (England, 1866)</td>
<td>Ocular nerve palsies in diabetes</td>
</tr>
<tr>
<td>Frederick Pavy (England, 1885)</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td>Julius Althaus (Germany, 1890)</td>
<td>Mononeuropathy</td>
</tr>
<tr>
<td>Thomas Davies Pryce (England, 1887)</td>
<td>Perforating foot ulcers</td>
</tr>
<tr>
<td>Nephropathy</td>
<td></td>
</tr>
<tr>
<td>Wilhelm Griesinger (Germany, 1859)</td>
<td>Renal disease in patients with diabetes</td>
</tr>
<tr>
<td>Paul Kimmelstiel and Clifford Wilson (USA, 1936)</td>
<td>Glomerulosclerosis associated with heavy proteinuria</td>
</tr>
</tbody>
</table>

Figure 1.1 The Ebers papyrus. Courtesy of the Wellcome Library, London.

Figure 1.2 (a) Clinical description of diabetes by Aretaeus of Cappadocia (2nd century AD). Adapted from Papaspyros NS (1952) The History of Diabetes Mellitus. (b) Sushrut (Susruta), an Indian physician who wrote medical texts with Charak (Charuka) between 500 BC and 400 BC.
unquenchable thirst, the “melting down of the flesh and limbs into urine” and short survival.

The Hindu physicians, Charak and Sushrut, who wrote between 400 and 500 BC, were probably the first to recognize the sweetness of diabetic urine (Figure 1.2b). Indeed, the diagnosis was made by tasting the urine or noting that ants congregated round it. Charak and Sushrut noted that the disease was most prevalent in those who were indolent, overweight and gluttonous, and who indulged in sweet and fatty foods. Physical exercise and liberal quantities of vegetables were the mainstays of treatment in the obese, while lean people, in whom the disease was regarded as more serious, were given a nourishing diet. The crucial fact that diabetic urine tasted sweet was also emphasized by Arabic medical texts from the 9–11th centuries AD, notably in the medical encyclopedia written by Avicenna (980–1037).

**The 17th and 18th centuries**

In Europe, diabetes was neglected until Thomas Willis (1621–1675) wrote *Diabetes, or the Pissing Evil* [1]. According to him, “diabetes was a disease so rare among the ancients that many famous physicians made no mention of it … but in our age, given to good fellowship and guzzling down of unallayed wine, we meet with examples and instances enough, I may say daily, of this disease.” He described the urine as being “wonderfully sweet like sugar or honey” but did not consider that this might be because it contained sugar.

The first description of hyperglycemia was in a paper published in 1776 by Matthew Dobson (1735–1784) of Liverpool (Figure 1.3) [2]. He found that the serum as well as the urine of his patient Peter Dickenson (who passed 28 pints of urine a day) tasted sweet. Moreover, he evaporated the urine to “a white cake [which] smelled sweet like brown sugar, neither could it by the taste be distinguished from sugar.” Dobson concluded that the kidneys excreted sugar and that it was not “formed in the secretory organ but previously existed in the serum of the blood.”

The Edinburgh-trained surgeon, John Rollo (d. 1809) was the first to apply the adjective “mellitus” (from the Latin word meaning “honey”). He also achieved fame with his “animal diet,” which became the standard treatment for most of the 19th century. Rollo thought that sugar was formed in the stomach.
introduced by Trommer in 1841, Moore in 1844 and – the best known – Fehling in 1848. Measurement of blood glucose could only be done by skilled chemists but needed so much blood that it was rarely used in either clinical care or research. It only became practicable with the introduction in 1913 of a micromethod by the Norwegian-born physician Ivar Christian Bang (1869–1918) and it was the ability to measure glucose repeatedly which led to development of the glucose tolerance test between 1913 and 1915.

Glucose metabolism was clarified by the work of Claude Bernard (1813–1878) [5], the Frenchman whose numerous discoveries have given him a special place in the history of physiology (Figure 1.5). When Bernard began work in 1843, the prevailing theory was that sugar could only be synthesized by plants, and that animal metabolism broke down substances originally made in plants. It was also thought that the blood only contained sugar after meals, or in pathologic states such as diabetes. Between 1846 and 1848, Bernard reported that glucose was present in the blood of normal animals, even when starved. He also found higher concentrations of glucose in the hepatic than in the portal vein, and “enormous quantities” of a starch-like substance in the liver which could be readily converted into sugar. He called this “gly-
that the dog, previously house-trained, was now incontinent of urine. Minkowski realized the significance of the polyuria, and tested the dog’s urine.

Possible explanations for the role of the pancreas were that it removed a diabetogenic toxin, or produced an internal secretion that controlled carbohydrate metabolism. The concept of “internal secretions” had been publicized in June 1889, by the well-known physiologist Charles-Édouard Brown-Séquard (1817–1894), who claimed to have rejuvenated himself by injections of testicular extract [9]. It was given further credence in 1891, when Murray reported that myxoedema could be cured by sheep thyroid extract by injection or orally.

In 1893, Gustave Laguesse suggested that the putative internal secretion of the pancreas was produced by the “islands” of cells scattered through the gland’s parenchyma [10], which had been discovered in 1869 by the 22-year-old Paul Langerhans (1847–1888) (Figure 1.7). Langerhans had described these clusters of cells, having teased them out from the general pancreatic tissue, but had not speculated about their possible function [11]; it was Laguesse who named them the “islets of Langerhans.” At this time, the glucose-lowering internal secretion of the islets was still hypothetical, but in 1909 the Belgian Jean de Meyer named it insulin (from the Latin for “island”) [12].

It would be wrong to give the impression that Minkowski’s experiments immediately established the pancreatic origin of diabetes. In fact, during the next two decades, it was widely agreed that diabetes was a heterogeneous disorder with various subtypes, and that its pathogenesis involved at least three organs: the brain, pancreas and liver [13]. The discovery by Blum in 1901 that injec-
Part 1 Diabetes in its Historical and Social Context

8

more like hypertensive retinopathy. In 1879, Stephen Mackenzie (1844–1909) and Sir Edward Nettleship (1845–1913) found microaneurysms in flat preparations of the retina and, in 1888, Nettleship described new vessels and the beaded appearance of retinal veins [15]. The full picture of diabetic retinopathy was described in 1890 by Julius Hirschberg (1843–1925) who was the first to claim that it was specific to diabetes [16].

Neuropathic symptoms in patients with diabetes had been mentioned by Rollo at the end of the 18th century, and in 1864 Charles Marchal de Calvi (1815–1873) concluded that nerve damage was a specific complication of diabetes. In 1885, the Guy’s Hospital physician, Frederick Pavy (1829–1911), gave a description of neuropathic symptoms which would grace any modern textbook [17]:

Figure 1.8 Pictures from Jaeger’s Atlas of the Optic Fundus, 1869 [14]. Top left: Bright’s disease. Top right: Jaeger’s retinitis hemorrhagica is now recognized as central retinal vein occlusion. Bottom left: A 22-year-old man with suspected diabetes. Bottom right: Central retinal artery occlusion. Courtesy of W.B. Saunders.
“The usual account given by these patients of their condition is that they cannot feel properly in their legs, that their feet are numb, that their legs seem too heavy – as one patient expressed it, “as if he had 20 lb weights on his legs and a feeling as if his boots were great deal too large for his feet.” Darting or “lightning” pains are often complained of. Or there may be hyperaesthesia, so that a mere pinching of the skin gives rise to great pain; or it may be the patient is unable to bear the contact of the seam of the dress against the skin on account of the suffering it causes. Not infrequently there is deep-seated pain located, as the patient describes it, in the marrow of the bones which are tender on being grasped, and I have noticed that these pains are generally worse at night.”

Pavy also recorded unusual presentations, including a 67-year-old who complained of “lightning pains on the right side of the waist” and cases in which the third nerve was affected with “dropped lid and external squint” [18].

Kidney disease was known to be relatively common in diabetes. In 1859, Wilhelm Griesinger (1817–1868) reported 64 autopsies in adults, half of whom had renal changes which he attributed to hypertension and atherosclerosis [19]; however, the histologic features of diabetic kidney disease and the importance of renal complications were not reported until the 1930s.

In the latter part of the 19th century it was becoming apparent that there were at least two clinically distinct forms of diabetes. In 1880, the French physician Etienne Lancereaux (1829–1910) identified lean and obese patients as having *diabète maigre* and *diabète gras* [20], and this observation laid the foundations for subsequent etiologic classifications of the disease.

### The 20th century

Murray’s cure of myxoedema in 1891 led to a belief that pancreatic extract would soon result in a cure for diabetes, but, in the face of repeated failures over the next 30 years, even believers in an antidiabetic internal secretion were depressed about the likelihood of isolating it, and diverted their attention to diet as a treatment for the disease.

Best known was the starvation regimen of Frederick Madison Allen (1876–1964), which Joslin (Figure 1.9) described in 1915 as the greatest advance since Rollo’s time [21]. This approach was
Part 1 Diabetes in its Historical and Social Context

an extreme application of one that had been proposed as early as 1875 by Apollinaire Bouchardat (1806–1886), who advocated intensive exercise and “manger le moins possible.” Starvation treatment did work in a limited sense, in that some patients could survive for many months or even years, instead of a few weeks or months with untreated type 1 diabetes. The quality of life, however, was very poor, and some patients died of malnutrition rather than diabetes. In 1921, Carl von Noorden (1858–1944) – proponent of the “oatmeal cure” – turned away in disapproval when he saw Joslin’s prize patient, 17-year-old Ruth A, who at just over 1.52 m in height weighed only 24.5 kg (a body mass index of 10.6 kg/m²).

Discovery of insulin

Many attempts were made between 1889 and 1921 to isolate the elusive internal secretion of the pancreas. These largely failed because the extracts were inactive or had unacceptable side effects; some preparations may have had limited biologic activity, but this was not recognized, either because hypoglycemia was misinterpreted as a toxic reaction or because blood glucose was not measured. Those who came closest were the Berlin physician, Georg Zuelzer (1840–1949) in 1907 [23], Ernest Scott (1877–1966) in Chicago in 1911 [24] and Nicolas Paulesco (1869–1931) in Romania in 1920–1921 [25] (Figure 1.10).

The story of how insulin was discovered in Toronto in 1921 is well known, at least superficially (Figure 1.11). A young orthopedic surgeon, Frederick Banting, inspired after reading an article by the pathologist Moses Barron (1884–1975), wondered whether the antidiabetic pancreatic principle was digested by trypsin during extraction, and decided to prevent this loss by ligating the pancreatic duct, thus causing the exocrine tissue to degenerate. He approached the Professor of Physiology in Toronto, J.J.R. Macleod, an authority on carbohydrate metabolism, who poured scorn on the idea and suggested that the only likely outcome would be “a negative result of great physiological importance.”

Eventually, Macleod relented and installed Banting in a rundown laboratory, later leaving for Scotland and a fishing holiday. A student, Charles Best, was chosen by the toss of a coin to help Banting. Within 6 months of this unpromising start, Banting and Best (referred to in Toronto academic circles as B2) had discovered the most important new therapy since the antisyphilitic agent Salvarsan. These events are described in detail in the excellent book by Michael Bliss [26].

Their approach began with the injection of extracts of atrophied pancreas (prepared according to Macleod’s suggestions) into dogs rendered diabetic by pancreatectomy. Subsequently, they discovered that active extracts could be obtained from beef pancreas which Best obtained from the abbatoir. The extraction procedure (using ice-cold acid-ethanol) was greatly refined by James B. (Bert) Collip, a biochemist who was visiting Toronto on sabbatical leave.

The first clinical trial of insulin (using an extract made by Best) took place on January 11, 1922, on 14-year-old Leonard Thompson, who had been on the Allen starvation regimen since 1919 and weighed only 30 kg (Figure 1.12). After the first injection, his blood glucose level fell slightly, but his symptoms were unchanged and he developed a sterile abscess. On January 23, he was given another extract prepared by Collip, and this normalized his blood glucose by the next morning; further injections over the next 10 days led to marked clinical improvement and complete elimination of glycosuria and ketonuria. Initial clinical results in seven cases were published in the March 1922 issue of the Canadian Medical Association Journal [27], which concluded dramatically that:

1 Blood sugar can be markedly reduced, even to normal values;
2 Glycosuria can be abolished;
3 The acetone bodies can be made to disappear from the urine;
4 The respiratory quotient shows evidence of increased utilization of carbohydrates;
5 A definite improvement is observed in the general condition of these patients and, in addition, the patients themselves report a subjective sense of well-being and increased vigor for a period following the administration of these preparations.

The term “insulin” was coined by Macleod, who was unaware of de Meyer’s earlier suggestion of insuline. News of its miraculous effects spread astonishingly rapidly [28]. In 1922, there were only 19 references in the world literature to “insulin” or equivalent terms such as “pancreatic extract”; by the end of 1923, there were 320 new reports, and a further 317 were published during the first 6 months of 1924.

By October 1923, insulin was available widely throughout North America and Europe. International recognition followed rapidly for its discoverers, and the 1923 Nobel Prize for Physiology or Medicine was awarded jointly to Banting and Macleod. Banting was angered by the decision, and announced publicly that he would share his prize with Best, whereupon Macleod decided to do the same with Collip.

The postinsulin era

It was confidently anticipated that insulin would do for diabetes in the young what thyroid extract had done for myxoedema, but it soon became obvious that insulin was a very different type of treatment. Thyroid was given once a day by mouth and at a fixed dosage. Insulin had to be injected in measured amounts which varied from day to day, and carried the ever-present danger of hypoglycemia. One often reads that insulin “revolutionized” the treatment of diabetes; it did so in the sense that it saved the lives of many who would otherwise have died, but its unforeseen effect was to transform an acute, rapidly fatal illness into a chronic disease with serious long-term complications. For example, only 2% of deaths among Joslin’s young patients with diabetes before 1937 were caused by kidney disease, while over 50% dying between 1944 and 1950 had advanced renal failure. Strategies to avoid and prevent the chronic complications of diabetes remain important scientific and clinical priorities today.
Causes and natural history of diabetes

The recognition that diabetes was not a single disease was important in initiating research that has helped to unravel the causes of hyperglycemia.

The broad etiologic subdivision into type 1 (juvenile-onset, or insulin-dependent) and type 2 diabetes (maturity-onset, or

The rest of this chapter highlights some developments that can be regarded as landmarks in the understanding and management of the disease: to some extent, this is a personal choice, and it is obvious from the other chapters in this book that the “history” of diabetes is being rewritten all the time.
non-insulin-dependent) stemmed ultimately from Lancereaux’s *diabète maigre* and *diabète gras* distinction, as well as observations soon after the discovery of insulin that some patients did not react “normally” to insulin. In the 1930s, Wilhelm Falta (1875–1950) in Vienna [29] and Harold Himsworth (1905–93) in London [30] proposed that some individuals with diabetes were more sensitive to the glucose-lowering effects of insulin, whereas others were insulin-insensitive, or insulin-resistant. The former were usually thin and required insulin to prevent ketoacidosis, while the latter were older, obese and ketosis-resistant.

The “insulin clamp” technique developed in the 1970s by Ralph DeFronzo *et al.* [31] in the USA was the first to measure rigorously the hypoglycemic action of insulin, and has led to countless studies of insulin resistance and its relationship to type 2 diabetes and vascular disease. Various groups, including DeFronzo’s, have helped to clarify the role of β-cell failure in type 2 diabetes, and how it relates to insulin resistance. Maturity-onset diabetes of the young (MODY) was recognized in 1974 by Robert Tattersall (b. 1943) as a distinct, dominantly inherited subset of type 2 diabetes [32]; since 1993, five different molecular defects have been identified in this condition.
The causes of the profound β-cell loss that led to the severe insulin deficiency of type 1 diabetes remained a mystery for a long time. "Insulitis", predominantly lymphocytic infiltration of the islets, was noted as early as 1901 by Eugene L. Opie (1873–1971) and colleagues [33], but because it was apparently very rare, found in only six of 189 cases studied by Anton Weichselbaum (1845–1920) in 1910, its importance was not appreciated. The possible role of insulitis in β-cell destruction was not suggested until 1965, by the Belgian Willy Gepts (1922–1991) [34]. The theory that type 1 diabetes results from autoimmune destruction of the β cells was first made in 1979 by Deborah Doniach (1912–2004) and GianFranco Bottazzo (b. 1946) [35]. Unlike other autoimmune endocrine diseases where the autoantibody persists, islet cell antibodies (ICA) turned out to be transient and disappeared within a year of the onset of diabetes. An unexpected finding from the Barts–Windsor prospective study of the epidemiology of diabetes in childhood started by Andrew Cudworth (1939–1982) was that ICA could be detected in siblings of young people with diabetes up to 10 years before they developed apparently acute-onset diabetes. This long lead-in period raised the possibility of an intervention to prevent continuing β-cell destruction. Cyclosporine in people with newly diagnosed type 1 diabetes prolongs the honeymoon period but without permanent benefit once the drug is stopped [36]. Nicotinamide and small doses of insulin (together with many other interventions) prevent diabetes in the non-obese diabetic (NOD) mouse but were without effect in relatives of people with type 1 diabetes with high titers of ICA [37,38].

From 1967, when Paul Lacy (1924–2005) showed that it was possible to "cure" diabetes in inbred rats with an islet cell transplant, it always seemed that the problem of islet cell transplantation in humans was about to be solved. Hope was rekindled in 2000 by a team in Edmonton, Canada. After 5 years 80% of their transplanted patients were producing some endogenous insulin but only 10% could manage without any injected insulin [39].

### Chronic diabetic complications

It had been assumed that arteriosclerosis caused chronic diabetic complications, but this notion was challenged by two papers published in the mid-1930s, which pointed to specific associations of diabetes with retinal and renal disease (Table 1.2). In 1934, Henry Wagener (1890–1961) and Russell Wilder (1885–1959) from the Mayo Clinic reported patients who had retinal hemorrhages but no other clinical evidence of vascular disease [40], and concluded that "The very existence of retinitis in cases in which patients have no other signs of vascular disease must mean that diabetes alone does something to injure the finer arterioles or venules of the retina, probably the latter."

In 1936, Paul Kimmelstiel (1900–1970) and Clifford Wilson (1906–1997) described the striking histologic finding of "intercapillary glomerulosclerosis" – large hyaline nodules in the glomeruli – in the kidneys of eight subjects at autopsy (Figure 1.13) [41]. Seven of the eight patients had a known history of diabetes, and Kimmelstiel and Wilson noted the common features of hypertension, heavy albuminuria with “œdema of the nephrotic type,” and renal failure. In fact, this paper led to considerable confusion during the next 15 years: according to one writer, the "Kimmelstiel–Wilson syndrome" came to mean all things to all men [42]. Nonetheless, it was significant because it drew attention to a specific diabetic renal disease.

Acceptance of the concept that diabetic angiopathy was specific to the disease owed much to the work of Knud Lundbaek of Aarhus in Denmark (Figure 1.14), who published his findings in a book in 1953–1954 and a paper in the Lancet in 1954 [43,44]. His key arguments were that long-standing diabetic vascular disease differed fundamentally from atherosclerosis, in that both sexes were equally affected and that microaneurysms, ocular phlebopathy and Kimmelstiel–Wilson nodules were unique to diabetes and usually occurred together.

---

**Table 1.2 Milestones in the scientific understanding of diabetes and its complications.**

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1906</td>
<td>Paul Kimmelstiel and Clifford Wilson described the striking histologic finding of &quot;intercapillary glomerulosclerosis&quot; – large hyaline nodules in the glomeruli – in the kidneys of eight subjects at autopsy (Figure 1.13) [41]. Seven of the eight patients had a known history of diabetes, and Kimmelstiel and Wilson noted the common features of hypertension, heavy albuminuria with “œdema of the nephrotic type,” and renal failure. In fact, this paper led to considerable confusion during the next 15 years: according to one writer, the &quot;Kimmelstiel–Wilson syndrome&quot; came to mean all things to all men [42]. Nonetheless, it was significant because it drew attention to a specific diabetic renal disease. Acceptance of the concept that diabetic angiopathy was specific to the disease owed much to the work of Knud Lundbaek of Aarhus in Denmark (Figure 1.14), who published his findings in a book in 1953–1954 and a paper in the Lancet in 1954 [43,44]. His key arguments were that long-standing diabetic vascular disease differed fundamentally from atherosclerosis, in that both sexes were equally affected and that microaneurysms, ocular phlebopathy and Kimmelstiel–Wilson nodules were unique to diabetes and usually occurred together.</td>
</tr>
</tbody>
</table>
The molecular and cellular mechanisms underlying diabetic tissue damage remain controversial after decades of intensive research. One of the early landmarks in this field was the work of J.H. Kinoshita (b. 1922) during the early 1970s, which pointed to the involvement of the polyol pathway in the formation of diabetic cataracts [45].

Physiology

In 1907, M.A. Lane, a student of Robert Bensley (1867–1956), Professor of Antatomy in Chicago, used conventional histologic techniques to distinguish two different cell types in the islet of Langerhans, which he termed A and B [46]. The hormones secreted by these respective cell types were not identified until much later (Table 1.2). Frank Young (1908–1988) and colleagues reported in 1938 that injections of anterior pituitary extract could induce permanent diabetes in the dog, and that this was accompanied by selective degranulation and loss of the β-cells [47]; it was surmised that these cells produced insulin, and this was finally confirmed using immuno-histochemistry by Paul Lacy in 1959 [48]. Glucagon was similarly localized to the α-cells in 1962 by John Baum and colleagues [49].

<table>
<thead>
<tr>
<th>Table 1.3 Milestones in the understanding of the causes of diabetes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Willis (England, 17th century)</td>
</tr>
<tr>
<td>Thomas Cawley (England, 1788)</td>
</tr>
<tr>
<td>Oskar Minkowski and Josef von Mering (Germany, 1889)</td>
</tr>
<tr>
<td>Etienne Lancereaux (France, 1880)</td>
</tr>
<tr>
<td>Eugene Opie (USA, 1900)</td>
</tr>
<tr>
<td>Eugene Opie (USA, 1910)</td>
</tr>
<tr>
<td>Wilhelm Falta (Vienna) and Harold Himsworth (England; early 1930s)</td>
</tr>
<tr>
<td>Willy Gepts (Belgium, 1965)</td>
</tr>
<tr>
<td>Deborah Doniach and Gianfranco Bottazzo (England, 1979)</td>
</tr>
<tr>
<td>Andrew Cudworth and John Woodrow (England, 1975)</td>
</tr>
<tr>
<td>Overindulgence in food and drink</td>
</tr>
<tr>
<td>Pancreatic stones cause diabetes</td>
</tr>
<tr>
<td>Pancreatectomy causes diabetes in the dog</td>
</tr>
<tr>
<td>Lean and obese diabetic subtypes distinguished</td>
</tr>
<tr>
<td>Hyaline degeneration (amyloidosis) of islets (type 2 diabetes)</td>
</tr>
<tr>
<td>Lymphocytic infiltration of islets (&quot;insulitis&quot;; type 1 diabetes)</td>
</tr>
<tr>
<td>Distinguished insulin-resistant and insulin-sensitive forms of diabetes</td>
</tr>
<tr>
<td>Suggested that insulitis caused β-cell destruction (type 1 diabetes)</td>
</tr>
<tr>
<td>Suggested that insulin-dependent diabetes is an autoimmune disease with specific HLA antigens</td>
</tr>
</tbody>
</table>
The amino acid sequence of insulin was reported in 1955 by Frederick Sanger in Cambridge, UK [50], and the three-dimensional structure of the molecule in 1969 by Dorothy Hodgkin, in Oxford [51]; both discoveries were recognized by the award of Nobel Prizes (Figure 1.15). The complete insulin molecule was synthesized from amino acids by Wang Ying-lai (1908–2001) and colleagues in Shanghai in 1965 [52]. The insulin precursor, proinsulin, was described in 1967 by Donald Steiner (b. 1930) in Chicago [53]. The first bioassay for insulin, based on the hormone’s ability to lower blood glucose in the alloxan-diabetic rat, was reported in 1950 by the Australian Joseph Bornstein (1918–1994), working in London with Robin D. Lawrence (see Fig. 1.20) [54]. This method was superseded in 1956 by Rosalyn Yalow and Solomon Berson in the USA, who discovered that insulin was antigenic; they exploited the binding of the hormone to anti-insulin antibodies to develop the first radio-immunoassay [55]. This assay method revolutionized endocrinology – and indeed, many areas of physiology and medicine – and was also rewarded with a Nobel Prize (Figure 1.16).

The sequence of rat insulin genes was described in 1977 by Axel Ullrich (b. 1945) and colleagues [56], and the human sequence by Graham Bell (b. 1948) and his group in 1980 [57]. The existence of insulin receptors was inferred from the insulin-binding characteristics of liver-cell membranes by Pierre Freychet (b. 1935) and colleagues in 1971 [58], and the receptor protein was isolated by Pedro Cuatrecasas (b. 1936) in the following year [59]. The gene encoding the insulin receptor was cloned and sequenced in 1985 by two groups [60,61]. In recent years, numerous advances have helped to clarify how insulin exerts its biologic actions. Among these was the discovery in 1985 of the first of the glucose transporter (GLUT) proteins by Mueckler and colleagues in the USA [62].

Management of diabetes

An objective observer surveying clinical diabetes during the half-century after the discovery of insulin and the “resurrection” (a word used by Joslin) of young people with diabetes would have been dismayed by what he saw (Table 1.4). In particular, young people were dying of complications that had previously been assumed to be the preserve of the elderly. Two particularly depressing papers were published in 1947 and 1950. First, Henry Dolger (1909–1997) in New York described 20 patients who fulfilled the then-accepted criteria for excellent diabetic control, but
who all developed severe retinopathy after 6–22 years [63]; among these was the first patient ever to receive insulin at Mount Sinai Hospital, New York, who also had heavy albuminuria and hypertension by the age of 32. Second, Ruth Reuting reported a cohort of 50 young patients originally identified in 1929 [64]. By 1949, one-third had died (mostly from cardiovascular and renal disease) at an average age of 25 years, after only 18 years of diabetes, and the survivors showed “ominous signs of hypertension, azotemia and proteinuria in significant numbers.” This had occurred despite the introduction of more versatile insulin preparations (see below); the situation was so hopeless that it inaugurated 20 years of treatment with “heroic” measures such as adrenalectomy and hypophysectomy.

These and other studies raised questions about whether lowering blood glucose levels to normal could prevent diabetic complications or reverse them once they had appeared. The hypothesis remained untestable for four more decades, until the means to achieve tight glycemic control and measure it had been devised.

**Insulin**

For the first decade after its discovery, insulin was available only in its soluble (regular) formulation, whose short-action profile required multiple daily injections. The first delayed-action preparation, protamine insulinate, was introduced in 1936 by Hans Christian Hagedorn in Denmark (Figure 1.17) [65]. This was followed by protamine zinc insulin later the same year, then...
globin insulin in 1939, NPH (neutral protamine Hagedorn, or isophane) in 1946, and the lente series in 1952. Long-acting insulins were welcomed by diabetes specialists and patients, but their use as a single daily injection probably produced worse glycemic control than three or four injections of soluble insulin. Indeed, delayed-action preparations were initially condemned by some diabetes specialists, such as Russell Wilder of the Mayo Clinic, because the patient could slip without apparent warning into hypoglycemia.

The number and variety of insulin preparations proliferated, but the main advances were in methods to produce highly purified preparations from porcine or bovine pancreas, which remained the source for therapeutic insulin until the early 1980s. Insulin was the first therapeutic protein to be produced by recombinant DNA technology, initially by David Goeddel (b. 1951), who expressed synthetic genes encoding the A- and B-chains separately in Escherichia coli and then combined these chemically to produce human-sequence insulin [66]. From there, genetic engineering has been used to produce “designer” insulins such as the fast-acting insulin analogs lispro and aspart and the “peakless” basal insulins such as glargine and detemir. How much these will improve glycemic control in the generality of people with diabetes is debatable; weekend golfers do not become champions when given expensive clubs!

Most people with diabetes still inject insulin subcutaneously. From the patient’s viewpoint, major milestones were the replacement of glass and steel syringes by disposable plastic syringes with fine-gauge needles, and then by “pen” injection devices invented by John Ireland (1933–1988) in Glasgow, Scotland, in 1981 [67]. Portable insulin infusion pumps were developed by John Pickup (b. 1947) and colleagues in London during the late 1970s [68], and have become progressively smaller and more sophisticated. Patients and manufacturers hope that there will eventually be an insulin that can be given without injection. The first inhaled insulin was marketed in 2006 but withdrawn a year later because of lack of demand and concerns about safety [69].

Oral hypoglycemic agents
The first orally active glucose-lowering drug, synthalin, a guanidine derivative, was developed by Frank and colleagues in Breslau in 1926 [70], but had to be withdrawn because of toxicity (a recurrent problem for oral hypoglycemic drugs). The sulfonylureas originated from the work of Auguste Loubatières (1912–1977) in France during the early 1940s on the glucose-lowering action of a sulfonamide derivative, 2254RP. Loubatières made the crucial observations that proved that these drugs act as insulin secretagogues and that they were effective in intact, but not in pancreatectomized, animals [71]. In 1955 carbutamide was the first sulfonylurea to enter clinical practice and tolbutamide followed in 1957. Phenformin, the first biguanide, was introduced in 1959 following research into the metabolic effects of guanidine derivatives which had built on Frank’s initial studies [72]. Metformin appeared on the European market in 1960 but was not marketed in the USA until 1994. Troglitazone, the first of a new class of antidiabetic drugs, the glitazones, was also marketed in 1994 but withdrawn because of liver damage. It was followed by rosiglitazone and pioglitazone. Another new class of drugs, acting on the incretin system, were introduced in 2005. These are either glucagon-like peptide 1 (GLP-1) agonists (such as exenatide) or inhibitors of the enzyme dipeptidylpeptidase-4 (DPP-4) which breaks down GLP-1 (gliptins).

Tolbutamide, phenformin and insulin were compared in the treatment of maturity-onset diabetes in the first randomized controlled trial, the University Group Diabetes Program [73–75]. This much-criticized study concluded that the death rate was higher for both oral agents than for placebo, and that insulin (whether given in a fixed or variable dose) was no better than placebo [75]. These findings were interpreted by some as suggesting that treatment of maturity-onset diabetes was a waste of time – a myth that was only laid finally to rest by the UK Prospective Diabetes Study.

Glucose control and treatment targets
During the 1920s, opinion leaders advocated normalizing blood glucose in young patients with diabetes, the rationale being to “rest” the pancreas, in the hope that it might regenerate. The only way of monitoring diabetic control was by testing the urine for glucose, and attempts to keep the urine free from sugar inevitably resulted in severe hypoglycemia and often psychologic damage. This led to the so-called “free diet” movement – linked particularly with Adolf Lichtenstein (Stockholm) and Edward Tolstoi (New York) – which encouraged patients to eat whatever they liked and not to worry about glycosuria, however heavy. Tolstoi’s view [76] was that a life saved by insulin should be worth living, and that patients should be able to forget that they had diabetes after each morning’s injection; it seems likely that many physicians followed this policy for the next 40 years.
Part 1  Diabetes in its Historical and Social Context

Part 1  Diabetes in its Historical and Social Context

Adult physicians were similarly ambivalent about the importance of good glycemic control. Only one-third of diabetes physicians questioned in England in 1953 thought that normoglycemia would prevent diabetic complications, and only one-half advised urine testing at home [77].

Practical monitoring of diabetic control became feasible in the late 1970s with the introduction into clinical practice of test strips for measuring blood glucose in a fingerprick sample and the demonstration that ordinary patients could use them at home [78,79]. The discovery of hemoglobin A1c by Samuel Rahbar (b. 1929) paved the way for glycated hemoglobin (HbA1c) assays which gave an objective measure of overall glucose control [80]. These methods in turn made possible the North American Diabetes Control and Complications Trial, which in 1993 finally established that good control prevents and delays the progression of microvascular complications in type 1 diabetes [81]. For type 2 diabetes, the importance of good glycemic control was definitively proved by another landmark study, the UK Prospective Diabetes Study (UKPDS), masterminded in Oxford, UK, by Robert Turner (Figure 1.18). The UKPDS reported in 1998, and not only showed a beneficial effect of improved glycemic control on microvascular complications [82], but also established the importance of treating hypertension [83]. By the late 1990s it was clear that reducing glucose levels, high blood pressure or cholesterol separately would reduce the frequency of heart disease and death and it was natural to wonder whether tackling them simultaneously (multiple risk factor intervention) would be even better. The Steno 2 study, which began in Denmark in 1992, enrolled patients with type 2 diabetes with microalbuminuria and after 13 years of follow-up showed that multiple risk factor intervention reduced the risk of death by 20% and the risk of developing nephropathy, retinopathy and neuropathy by 50% [84].

Diabetic complications
Apart from the general benefits of controlling blood glucose, some specific treatments have emerged for certain chronic complications. Well-conducted clinical trials during the late 1970s showed the effectiveness of laser photocoagulation in preventing visual loss from both maculopathy and proliferative retinopathy [85]. This technique was derived from the xenon arc lamp originally described in the late 1950s by Gerd Meyer-Schwickerath (1921–92) of Essen, Germany [86].

The importance of blood pressure control in preventing the progression of nephropathy is now fully recognized, and angiotensin-converting enzyme inhibitors may be particularly beneficial; that blood pressure control slowed the progression of nephropathy was shown in studies by Carl-Erik Mogensen (b. 1938) and Hans-Henrik Parving (b. 1943) published in the early 1980s [87]. The measurement of low albumin concentrations in urine (microalbuminuria), now used throughout the world to screen for and monitor the course of diabetic nephropathy, is derived from a radioimmunoassay developed in 1969 by Harry Keen and Costas Chlouverakis, at Guy’s Hospital in London [88].

Figure 1.18  Robert Turner (1939–1999), instigator of the UKPDS, the first study to show that good control of blood glucose and blood pressure was beneficial in type 2 diabetes. Courtesy of the British Diabetic Association.

Diabetic ketoacidosis
The introduction of insulin was only one aspect of the management of this acute and previously fatal complication of diabetes. Of the first 33 cases treated by Joslin and his colleagues between January 1, 1923 and April 1, 1925, 31 survived – an excellent outcome, even by modern standards, which Joslin [89] attributed to: “Promptly applied medical care, rest in bed, special nursing attendance, warmth, evacuation of the bowels by enema, the introduction of liquids into the body, lavage of the stomach, cardiac stimulants, and above all the exclusion of alkalis.”

Sadly, other centers did not pay so much attention to detail. In 1933, the death rate from ketoacidosis in Boston was only 5%, but elsewhere in North America and Europe it averaged 30% and could be as high as 75%. An important advance in management was the acceptance of relatively low-dose insulin replacement, following the example of Ruth Menzel and colleagues in Karlsburg, Germany [90]. This broke with the tradition of high-dose regimens such as that proposed by Howard Root in the USA,
which had recommended an average of 1200 U insulin during the first 24 hours of treatment [91]. Another step forward was the recognition by Jacob Holler in 1946 of the danger of hypokalemia [92]. Holler’s observation helped to establish the need for monitoring plasma potassium levels, which became feasible with the introduction of the flame photometer, and replacing potassium accordingly.

**Diabetic pregnancy**

As late as 1950, the outcome of pregnancy in women with diabetes was still very poor in most units, with perinatal fetal losses of 45–65%, some 10 times higher than in the general population. Exceptions to this depressing rule were the units run by Priscilla White at the Joslin Clinic in Boston, who had published excellent results as early as 1935 [93], and by Jørgen Pedersen in Copenhagen (Figure 1.19). Pedersen identified the common features underpinning success as good diabetic control and care provided by an experienced and dedicated team consisting of a physician, obstetrician and pediatrician [94]. Pedersen’s target of a fetal mortality rate of 6% was not achieved in most European or US units until the 1980s.

**Delivery of care for people with diabetes**

From the earliest days of insulin injection and urine testing, it was apparent that people with diabetes needed knowledge and practical skills to manage their disease effectively. Lip-service was often paid to the importance of diabetes education, but most patients were badly informed. In 1952, Samuel Beaser (1910–2005) questioned 128 patients attending the Boston Diabetes Fair, and found that “all were distinctly deficient in knowledge of their disease” [95]; he felt that responsibility lay with both doctors and administrators. Further studies during the 1960s by Donnell Etzwiler (1927–2003) in Minneapolis showed that many doctors and nurses were also ignorant about managing diabetes. Since the

![Figure 1.19 Jørgen Pedersen (1914–1978) and Ivo Drury (1905–1988), pioneers, with Priscilla White (1900–1989), in the management of pregnancy in women with type 1 diabetes. Courtesy of Dr. Carl Erik Mogensen and the Royal College of Physicians of Ireland.](image_url)
1980s, diabetes specialist nurses and nurse educators have been appointed in increasingly large numbers – thus fulfilling a suggestion originally made by Joslin in 1916.

National and international diabetes associations have also played an important part by supporting scientific and clinical research, providing practical and moral help for patients, and lobbying governments on patients’ behalf. The first of these organizations was the Portuguese Association for the Protection of Poor Diabetics, founded in 1926 by Ernesto Roma of Lisbon after an inspiring visit to Joslin’s clinic in Boston (Figure 1.20). The Association’s aim was to provide free insulin and education for people with diabetes and their families. In the UK, the Diabetic Association (later the British Diabetic Association, and now Diabetes UK) was established in 1934 by Robin Lawrence of King’s College Hospital, London, helped by the novelist H.G. Wells (Figure 1.20). Similar organizations were later founded in France (1938), the USA (1940) and Belgium (1942), and now exist in most countries.

On a wider scale, the International Diabetes Foundation was established in 1950 and the European Association for the Study of Diabetes (EASD) in 1964. These organizations are devoted to the practice of diabetes care as well as the basic and clinical science of the disease, and have been valuable in coordinating treatment targets and strategies at international level; an important example was the St. Vincent Declaration, issued jointly in 1990 by the EASD and the World Health Organization [96].

References

3. Rollo J. An Account of Two Cases of the Diabetes Mellitus, With Remarks as They Arose During the Progress of the Cure. London: C. Dilly, 1797. [A 2nd edition with more cases was published in 1798 and a 3rd edition in 1806.]
Chapter 1

History of Diabetes Mellitus


24 Hetenyi G. The day after: how insulin was received by the medical profession. *Perspect Biol Med* 1995; 38:396–405.


42 Lane MA. The cytological characters of the areas of Langerhans. *Am J Anot* 1907; 7:409–421.


Part 1 Diabetes in its Historical and Social Context


64 Reuting RE. Progress notes on fifty diabetic patients followed 25 or more years. *Arch Intern Med* 1950; 86:891–897.


Further reading


Websites

**General history of diabetes**
http://pr15.mphy.lu.se/Diahistory1.html  
http://www.diabetes/living.com/basics/histdev.htm

**Discovery of insulin**
Discovery of Insulin website: http://web.idirect.com/~discover  
Nobel Prize Website: http://www.nobel.se/medicine/lauareates/1923

Archives

The notebooks and personal papers of the discoverers of insulin are preserved at the Thomas Fisher Rare Book Library, University of Toronto, Canada.